- Home
- BNZI vs CERO Comparison
BNZI vs CERO Comparison
Compare BNZI & CERO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BNZI
- CERO
- Stock Information
- Founded
- BNZI 2016
- CERO 2017
- Country
- BNZI United States
- CERO United States
- Employees
- BNZI N/A
- CERO N/A
- Industry
- BNZI
- CERO
- Sector
- BNZI
- CERO
- Exchange
- BNZI Nasdaq
- CERO Nasdaq
- Market Cap
- BNZI 11.5M
- CERO 9.6M
- IPO Year
- BNZI N/A
- CERO N/A
- Fundamental
- Price
- BNZI $2.46
- CERO $5.92
- Analyst Decision
- BNZI Strong Buy
- CERO Strong Buy
- Analyst Count
- BNZI 1
- CERO 2
- Target Price
- BNZI $240.00
- CERO $45.00
- AVG Volume (30 Days)
- BNZI 402.9K
- CERO 258.5K
- Earning Date
- BNZI 08-14-2025
- CERO 08-22-2025
- Dividend Yield
- BNZI N/A
- CERO N/A
- EPS Growth
- BNZI N/A
- CERO N/A
- EPS
- BNZI N/A
- CERO N/A
- Revenue
- BNZI $9,021,543.00
- CERO N/A
- Revenue This Year
- BNZI $337.60
- CERO N/A
- Revenue Next Year
- BNZI $91.81
- CERO N/A
- P/E Ratio
- BNZI N/A
- CERO N/A
- Revenue Growth
- BNZI 107.94
- CERO N/A
- 52 Week Low
- BNZI $2.35
- CERO $5.41
- 52 Week High
- BNZI $112.00
- CERO $895.40
- Technical
- Relative Strength Index (RSI)
- BNZI 32.88
- CERO 26.39
- Support Level
- BNZI $3.06
- CERO $8.07
- Resistance Level
- BNZI $3.43
- CERO $7.60
- Average True Range (ATR)
- BNZI 0.29
- CERO 0.48
- MACD
- BNZI -0.01
- CERO -0.17
- Stochastic Oscillator
- BNZI 7.19
- CERO 14.74
About BNZI Banzai International Inc.
Banzai International Inc is a marketing technology (MarTech) company that produces data-driven marketing and sales solutions for businesses of all sizes. Its mission is to help its customers accomplish their mission by enabling marketing, sales and customer engagement outcomes. The company has two reportable operating segments, Banzai Operating and OpenReel. The company's segments deliver SaaS tools that leverage data, analytics, and AI to provide marketing and sales solutions for business of all size. it derives maximum revenue from Banzai Operating segment. Geographically, it operates in Americas, Europe, Middle East and Africa (EMEA), and Asia Pacific.
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy. Its lead molecule is CER-1236, an autologous T-cell product that targets a novel tumor antigen, TIM-4 ligand.